Clinical Trial Update: Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma

View source ↗

Summary

This clinical trial update describes a real-world study of zolbetuximab in patients with HER-2 negative, Claudin-18.2–positive metastatic gastric or gastroesoph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Zolbetuximab (zolbetuximab)

Snippet

Sponsor: European Institute of Oncology | Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Status: RECRUITING